How should we use ibrutinib in patients with mantle cell lymphoma?
(2021) In British Journal of Haematology 193(3). p.445-446
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/fc25d6ba-ae45-4b1e-817b-208240a6499c
- author
- Jerkeman, Mats LU
- organization
- publishing date
- 2021-05-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Haematology
- volume
- 193
- issue
- 3
- pages
- 2 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85102317050
- pmid:33694156
- ISSN
- 0007-1048
- DOI
- 10.1111/bjh.17364
- language
- English
- LU publication?
- yes
- id
- fc25d6ba-ae45-4b1e-817b-208240a6499c
- date added to LUP
- 2021-03-29 08:14:05
- date last changed
- 2025-01-13 05:49:49
@misc{fc25d6ba-ae45-4b1e-817b-208240a6499c,
author = {{Jerkeman, Mats}},
issn = {{0007-1048}},
language = {{eng}},
month = {{05}},
number = {{3}},
pages = {{445--446}},
publisher = {{John Wiley & Sons Inc.}},
series = {{British Journal of Haematology}},
title = {{How should we use ibrutinib in patients with mantle cell lymphoma?}},
url = {{http://dx.doi.org/10.1111/bjh.17364}},
doi = {{10.1111/bjh.17364}},
volume = {{193}},
year = {{2021}},
}